surmount-1 trial tirzepatide non-diabetic weight loss obesity SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes For the first time, tirzepatide – Tirzepatide after intensive lifestyle intervention

Reach: 60 - 100 Million people (The Affluent India cohort)

Structure Therapeutics is among the most advanced challengers, with its oral GLP-1 receptor agonist aleniglipron generating Phase 2 data that has drawn significant industry attention

The SURPASS trials in diabetes populations showed significant weight loss alongside glycemic control, but the weight loss was generally slightly less than in the SURMOUNT obesity trials (participants without diabetes)

Benzodiazepines work by decreasing the physical symptoms of generalized anxiety disorder, such as muscle tension and restlessness

For more information, visit CostcoWeightLoss.com